MedTrace Logo

Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies

NCT05510089 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2023-10-10

No results posted yet for this study

Summary

This is a single-arm, multicenter, exploratory clinical study to evaluate the safety and efficacy of the combination of etoposide, cytarabine and PEG-rhG-CSF (EAP regimen) on hematopoietic stem cell mobilization in poor mobilization patients with hematological malignancies. All eligible patients will receive EAP regimen treatment, then the number of CD34+ cells and white blood cells will be monitoring. When the collection standard is met, hematopoietic stem cell collection will be started.

Conditions

  • Hematological Malignancy

Interventions

DRUG

Etoposide

D1\~D2: 75mg/m\^2

DRUG

Cytarabine

D1\~D2: 300mg/m\^2, q12h

DRUG

PEG-rhG-CSF

D6: 6mg

Sponsors & Collaborators

  • The Affiliated People's Hospital of Ningbo University

    lead OTHER_GOV

Principal Investigators

  • Ying Lu · The Affiliated People's Hospital of Ningbo University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2024-05-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05510089 on ClinicalTrials.gov